Immutep S.A. thinks it may have identified a niche opportunity for its LAG-3 immunotherapy in head-and-neck cancer, albeit from a small and non-controlled sample of a Phase IIb study that earlier this year yielded uninspiring data. The Australian company and analysts are contending that eftilagimod alfa, in combination with Merck & Co., Inc.’s Keytruda (pembrolizumab), might offer a chemotherapy-sparing regimen that would offer comparable efficacy in a tough-to-treat patient population with better safety and tolerability.
Key Takeaways
-
Hoping to find a path forward after a disappointing Phase II trial in head-and-neck cancer, Immutep finds that its LAG-3 agent combined with Keytruda bests Keytruda monotherapy in PD-L1-negative patients.
At the European Society of Medical Oncology virtual plenary session on 11 July, Immutep reported that eftilagimod produced a 35.5%...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
